Rheumatoid arthritis and malignant lymphomas.

Area of Science:

• Rheumatology
• Oncology
• Immunology

Background:

• Rheumatoid arthritis (RA) patients face an elevated risk of lymphoma, a concern amplified by reports of lymphomas in patients treated with TNF-blockers.
• The precise reasons behind this increased lymphoma risk in RA patients remain incompletely understood.
• This review consolidates current data on the associations between RA, lymphoma, and various treatment modalities, alongside RA disease-related risk factors.

Purpose of the Study:

• To review and summarize existing data on the association between rheumatoid arthritis and lymphoma risk.
• To evaluate the potential role of RA disease activity, specific treatments (including methotrexate and TNF-blockers), and other factors in lymphoma development.
• To provide insights for rheumatologists regarding lymphoma risk in RA patients.

Main Methods:

• Literature review of studies investigating lymphoma risk in rheumatoid arthritis patients.
• Analysis of data concerning RA disease activity, disease-modifying drugs (DMARDs), TNF-blockers, and Epstein-Barr virus (EBV) presence.
• Synthesis of findings to assess the contribution of disease severity versus treatment regimens to lymphoma risk.

Main Results:

• Recent studies suggest a correlation between increased RA disease activity and higher lymphoma risks.
• Evidence does not strongly support the hypothesis that disease-modifying drugs, particularly methotrexate, significantly increase lymphoma risk.
• While observation periods for TNF-blocking therapies are limited, current data do not indicate a clear increase in lymphoma risk.
• Epstein-Barr virus (EBV), detected via EBER in situ hybridization, appears infrequently in RA-associated lymphomas.
• A hypothetical link between increased self or non-self antigen-driven proliferation and lymphoma development in RA patients requires further investigation.

Conclusions:

• Rheumatologists must remain vigilant about the heightened lymphoma risk in patients with rheumatoid arthritis.
• The underlying cause of increased lymphoma risk in RA is still unclear, but evidence leans towards RA disease severity rather than specific treatments.
• Structured surveillance for patients undergoing new treatments is recommended to better evaluate future lymphoma risks, incorporating data on RA disease activity and severity.